← Leaderboards
Jason John Luke
University Of Pittsburgh At Pittsburgh
$2,704,650
Attributed
$5,461,112
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,461,112 · 3
By mechanism
UM1$2,668,701 · 1
R01$1,802,725 · 1
P30$989,686 · 1
Top collaborators
- Liza Cosca Villaruz5 shared
- Riyue Bao3 shared
- Jan Hendrik Beumer3 shared
- John C Byrd2 shared
- Farshid Dayyani2 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Jan Hendrik Beumer$5,486,814
- Hassane M Zarour$16,372,397
- Brian M Miller$139,570
- Yu Leo Lei$8,848,025
- John F McDyer$10,518,722
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsPharmaceutical PreparationsUniversitiesMalignant NeoplasmsCancer CenterBiological MarkersLeadershipResponseCatchment AreaProgramsEnrollmentMolecularTumorMissionConduct Clinical TrialsRegimenInvestigationInfrastructureAdultInstitutionPennsylvaniaEarly Phase Clinical TrialEarly Therapeutic-Clinical Trials NetworkModality
Grant awards (10)
Clinical Protocol and Data Management$485,600
P30 · FY2025 · CA · contact PI
NCI ETCTN Pittsburgh Cancer Consortium (PCC)$468,866
UM1 · FY2025 · CA
Immune Exclusion in Cancer Immunotherapy$592,843
R01 · FY2024 · DE
Clinical Protocol and Data Management$504,086
P30 · FY2024 · CA · contact PI
NCI ETCTN Pittsburgh Cancer Consortium (PCC)$442,721
UM1 · FY2024 · CA
NCI ETCTN Pittsburgh Cancer Consortium (PCC)$611,743
UM1 · FY2023 · CA
Immune Exclusion in Cancer Immunotherapy$604,941
R01 · FY2023 · DE
Immune Exclusion in Cancer Immunotherapy$604,941
R01 · FY2022 · DE
CATCH-UP: NCI ETCTN Pittsburgh Cancer Consortium (PCC)$400,000
UM1 · FY2022 · CA
NCI ETCTN Pittsburgh Cancer Consortium (PCC)$745,371
UM1 · FY2020 · CA